

## ICH Q6(R1) EWG Work Plan

*July 11, 2025*

**Topic Adoption date:** *June 2021*

**Rapporteur:** *Ms. Silmara Cristiane da Silveira Andreoli, ANVISA, Brazil/ Dr. Olivier Dirat, PhRMA*

**Regulatory Chair:** *Dr. Robin Levis, FDA, United States*

**Last Face-to-Face Meeting:** *Madrid, Spain, May 2025*

### 1. Key milestones

#### 1.a. Current status of key milestones

Past completion date	Milestone
<i>Jul. 2021</i>	<i>Topic adoption by ICH Assembly</i>
<i>Feb. 2024</i>	<i>Establishment of Q6(R1) Informal Working Group</i>
<i>Jul. 2024</i>	<i>Concept paper endorsed by ICH MC and transition to Expert Working Group (EWG)</i>

#### 1.b. Key Deliverables

MC Approval Date	Deliverable
<i>Jun. 2024</i>	<i>Q6(R1) Guideline</i>
<i>Jun. 2024</i>	<i>Q6(R1) Training Material</i>

#### 1.c. Future anticipated key milestones

Expected future completion date	Milestone
<i>Jan. 2026</i>	<i>Training material preparation initiated</i>
<i>Jun. 2026</i>	<i>Step 1 and 2a/b Sign-off of Q6(R1) draft Technical Document</i> <i>Initiate work on training materials</i>
<i>Jun. 2028</i>	<i>Step 3 and 4 Sign-off and Adoption of the Q6(R1) Guideline</i>

## 2. Timeline for specific tasks

Beginning date	End date	Task / Activity	Details
<i>Jul. 2025</i>	<i>Nov. 2025</i>	<i>Finalize draft text, including annexes</i>	<i>Finalize the draft of the Q6(R1) guideline for constituents' review</i>